Pfizer Inc. (pfe)
PFE — Company Overview
Investors tracking PFE follow a Drug Manufacturers - General name listed on NYQ within Healthcare.
| Ticker | PFE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYQ |
| Market cap | $149.33B |
| Last price | $26.20 |
| Size category | Large Cap |
PFE — Business Description
The business profile of Pfizer Inc. (PFE) reflects its role in Drug Manufacturers - General. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprisin…
Official website: https://www.pfizer.com.
PFE — Investment Thesis
Pfizer Inc. (PFE) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.
- Revenue is expanding at roughly 2.6% year-over-year (public data).
- Trailing P/E of 34.03× sits in a moderate band relative to high-growth peers.
- Forward P/E (9.13×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 6.7% adds an income component to total return.
- Equity market capitalization is approximately $149.33B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
PFE — Financial Health
PFE financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 6.8% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $12.49B supports balance-sheet flexibility.
| Trailing P/E | 34.03× |
| Forward P/E | 9.13× |
| Price / Sales | 2.34× |
| Price / Book | 1.75× |
| Gross margin | 74.7% |
| Operating margin | 27.9% |
| Profit margin | 6.8% |
| Return on equity | 5.0% |
| Debt / Equity | 74.25 |
| Free cash flow | $12.49B |
PFE — Growth Outlook
Growth outlook for Pfizer Inc. (PFE) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 2.6% suggests steady but measured expansion.
- Price is 8.9% below the 52-week high.
- Shares trade 11.1% above the 52-week low — limited rebound so far.
PFE — Competitive Position
Pfizer Inc. (PFE) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $149.33B places PFE among large-cap peers.
- Gross margin near 74.7% may reflect pricing power or favorable mix.
PFE — Strengths
Strengths for Pfizer Inc. (PFE) inferred from public financial metrics:
- Gross margin of 74.7% supports competitive unit economics.
- Positive free cash flow ($12.49B).
- Dividend yield of 6.7% for income-oriented holders.
- Moderate leverage (debt/equity 74.25).
- Large Cap scale ($149.33B) may provide distribution and funding advantages.
PFE — Weaknesses
Weaknesses and pressure points for Pfizer Inc. (PFE) based on available data:
Insufficient public data to assess this factor.
PFE — Opportunities
- Trading 11.1% above the 52-week low — potential recovery if fundamentals stabilize.
- Dividend yield of 6.7% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
PFE — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
PFE — Summary
Pfizer Inc. (PFE) is a large-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $26.20 with market cap $149.33B. Trailing P/E 34.03×. Revenue grew 2.6% year-over-year per public data. Notable strengths include gross margin of 74.7% supports competitive unit economics. For analyst estimates, ownership, and live news on PFE, upgrade to Vest Terminal Professional.
Pfizer Inc. FAQ
What does Pfizer Inc. (PFE) do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiova…
What is PFE's P/E ratio?
Pfizer Inc. has a trailing P/E of 34.03× based on publicly available market data.
Does PFE pay a dividend?
Indicated dividend yield: 6.7%. Confirm ex-dates and payout history in Vest Terminal.
What sector is PFE in?
Pfizer Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is PFE's market capitalization?
Approximate market cap: $149.33B.
What are the main risks for PFE?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of PFE?
Potential positives include gross margin of 74.7% supports competitive unit economics, positive free cash flow ($12.49b).
Where can I get analyst estimates for PFE?
Consensus estimates, price targets, and detailed analyst data for Pfizer Inc. are available to Professional subscribers in Vest Terminal — not on this public summary page.